Major Depression Clinical Trial
Official title:
Wake and Light Therapy to In-patients With Major Depression: A Randomized Controlled Trail, Efficacy, Predictors and Patient Experiences
The objective of the study is to examine whether a combination of wake therapy, light therapy and sleep time stabilization as a supplement to standard treatment can reduce depressive symptoms in patients admitted at two psychiatric wards at Aarhus University Hospital, Risskov. Seventy-four patients will be randomized either to this intervention or to a control group receiving treatment as usual. Furthermore, it will be examined whether the duration of admission can be reduced in the intervention group. Finally, the aim is to identify predictors of good effect of the intervention.
Background: About 150,000 Danes will constantly have symptoms of depression, and 20% of
those are admitted to a psychiatric hospital at least once. When admitted, the patients are
highly tormented and many have suicide thoughts. The treatment of depression in a ward
consists of beginning or adjustment of antidepressive medication combined with for instance
milieu therapy, psychotherapy and exercise offers. Full effect of medical treatment is only
reached after 4-6 weeks, and no quicker effect is documented in the other treatment methods.
Therefore, methods are needed which quickly, effectively and without large side effects can
reduce the symptoms. Wake therapy is a treatment method which has appeared to stop or reduce
depressive symptoms within hours, and several studies have demonstrated that up to 66% of
the patients responded to wake therapy. The method consists in the patients staying awake
for one night and the following day, in all 36 hours, which is followed by one night of
sleep. Light therapy and stabilisation of circadian rhythm have been shown to maintain the
effect of wake therapy.
Objective: To examine the efficacy of using wake and light therapy as a supplement to
standard treatment of hospitalised patients with depression and to identify the
characteristics of patients who accept and respond well to the treatment.
Methods: The project is carried out as a randomised controlled study and will include 74
patients with bipolar or unipolar depression. The patients are randomised to standard
treatment or to the intervention, which besides standard treatment will consist of three
times wake therapy in one week and 30 minutes daily light treatment in the entire nine week
study period as well as ongoing guidance in good sleep hygiene. Raters for the Hamilton
rating will be blinded to the treatment assignment.
Outcome: Primary outcome criteria will be the response rate in week two. Response is defined
as a 50 % reduction or more compared to the baseline score in HAM-D 17. Secondary outcomes
will be the remission rate in week two, the length of admission and the percentage of
patients with response and remission in week nine.
Variables and Assessment: Severity of depression will be assessed by using the
interview-based Hamilton Depression Rating scale, both the 17 item and the 6 item version.
For patient-reported outcome measures the Major Depression Inventory (MDI) and the World
Health Organisation (WHO)-5 wellbeing Index (WHO-5) will be used. Social and Occupational
Functional Assessment Scale (GAF) and Bech-Rafaelsen mania scala (MAS) will also be
recorded.
Data analysis: Data will be analysed in SPSS and presented descriptively in the two Groups
to show whether the randomisation succeeded. A "intention to treat" analysis will be
conducted, and on the basis of a requisite analysis a t-test, Mann-Whitney-Wilcoxon test or
chi2-test will be used. The association between predictive factors and response to wake
therapy will be described with prevalence proportions, ratios and will be analysed with a
chi2-test. The level of statistical significance will be set at 5 %. The randomisation will
be computer-generated, and the patients will be randomly allocated to the intervention group
or the control group.
Sample size: The literature shows response rates at 41% after two weeks in the intervention
group and 13 % in the control group. A power analysis based on these rates show that if α =
0,05 and β = 0,80, 37 patients should be included in each group, totally 74 patients.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00149110 -
Chronos: the Use of Chronobiological Treatment in Depression
|
N/A |